PSA (prostate cancer screening / surveillance context — USPSTF C-grade)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`BIO-PSA-PROSTATE-SCREENING`
Type	Biomarker
Aliases	PSA screeningProstate-Specific Antigen for Screeningserum PSAПСА (скринінг/нагляд раку передміхурової залози — USPSTF C)
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-PROSTATE`
Sources	`SRC-NCCN-PROSTATE-2025` `SRC-USPSTF-PROSTATE-2018`

Biomarker Facts

Biomarker type	serum_marker
Measurement	MethodSerum immunoassay (ECLIA, CLIA); WHO 96/670 calibration preferred Unitsng/mL Typical range 0 4
Related biomarkers	`BIO-PSA`

Notes

Screening-context entry for PSA — separate from BIO-PSA (which covers diagnostic and treatment-monitoring dynamics for established prostate cancer). USPSTF 2018: Grade C for men 55-69 (individualized shared-decision-making about benefits + harms); Grade D for men ≥70 (recommend AGAINST routine screening). NCCN 2025 (Early Detection): baseline PSA + DRE discussion at age 45 for African American men or BRCA2 carriers (high-risk groups), age 50 for average risk; if PSA <1 ng/mL, repeat every 2-4 years; if PSA 1-3 ng/mL, repeat every 1-2 years; if PSA >3 ng/mL, evaluate further (repeat PSA, mpMRI, biomarker reflex such as 4Kscore/PHI, possible biopsy). Higher screening intensity for confirmed BRCA2 germline carriers (IMPACT study — PSA q1y starting age 40; biopsy threshold ≥3 ng/mL). PSA can be falsely elevated in BPH, prostatitis, urinary retention, recent instrumentation. Free PSA ratio, PSA density, and reflex biomarkers (PHI, 4Kscore, SelectMDx) reduce unnecessary biopsy. Limitations: overdiagnosis/overtreatment of indolent cancers (well-characterized harm — driver of USPSTF Grade C). STUB pending two-Co-Lead signoff.

Used By

Actionability

BMA-PSA-PROSTATE-USPSTF-SHARED-DECISION - PSA screening for prostate cancer carries a USPSTF Grade C recommendation for men aged 55...